Key result
Makandi Ghana vati shows no benefit over Churna tablets for improving geriatric hypertension.
Why the study?
Hypertension is a common psychosomatic disorder in the geriatric population, and the clinical efficacy of Coleus forskohlii (Makandi) in this group needed evaluation.
Does Coleus forskohlii Ghana vati improve blood pressure and symptoms compared to Churna tablet in geriatric patients with hypertension?
Does Coleus forskohlii Ghana vati improve blood pressure and symptoms compared to Churna tablet in geriatric patients with hypertension?
Absolute Event Rate: 76.19% vs 75%
Coleus forskohlii in both Ghana vati and Churna tablet forms may provide mild improvement in hypertension and related symptoms in geriatric patients.
May support adjunctive Makandi in geriatric hypertension; leaves open efficacy confirmation in larger RCTs.
Hypertension is the most common psychosomatic disorder affecting 972 million people worldwide. The present clinical study deals with the effect of Makandi (Coleus forskohlii (Willd.) Briq.) Ghana vati and tablets of its powder in hypertension found in the geriatric age group (50-80 years). A total of 49 hypertensive patients fulfilling the diagnostic criteria were registered in two groups-Group I (Ghana vati) and Group II (Churna tablet). Out of 27 enrolled patients of group I, 21 patients completed the treatment. In Group II, out of 22 registered patients, a total of 20 patients completed the treatment. The effect of the therapy was assessed on the basis of changes in the systolic and diastolic blood pressures, in both sitting and supine positions; with Manasa Bhava Pariksha, Manasa Vibhrama Pariksha, symptomatology, geriatric signs and symptoms, and a brief psychiatric rating scale. Analysis of the results showed that the treatment in both the groups had been found to be good. It can be stated that Makandi, either in Ghana vati form or in churna tablet form, is an effective remedy for the treatment of hypertension. On analyzing the overall effect, 76.19% patients in Group I and 75.00% patients in Group II were mildly improved. Comparatively the overall treatment with group I was found to be better.
No takes yet. Share an insight, caveat, or question.
Jagtap et al. (2011) studied Hypertension (n=49). Makandi (Coleus forskohlii) Ghana vati vs. Makandi (Coleus forskohlii) Churna tablet was evaluated on Mild improvement in overall effect. Makandi (Coleus forskohlii) in Ghana vati form resulted in mild improvement in 76.19% of geriatric patients with hypertension, compared to 75.00% with Churna tablets.
Synapse has enriched 5 related papers. Consider them for comparative context: